All content on this page is intended strictly for research and educational purposes. All peptides referenced are research compounds supplied for laboratory use only and are not licensed for human therapeutic use. No information here constitutes medical advice, treatment recommendations, or clinical guidance. Researchers should consult applicable regulatory frameworks before designing any study involving these compounds.
Long COVID biology: the multisystem pathological landscape
Post-COVID condition (long COVID, PASC — post-acute sequelae of COVID-19) is characterised by persistent symptoms lasting more than 12 weeks after acute SARS-CoV-2 infection, affecting an estimated 10–30% of individuals with symptomatic COVID-19. The biological mechanisms underlying long COVID are heterogeneous and likely multifactorial — proposed drivers include persistent viral reservoir activation (SARS-CoV-2 RNA detectable in gut and lymph node tissue), T-cell exhaustion and immune dysregulation, mitochondrial dysfunction in immune and skeletal muscle cells, microbiome disruption with gut barrier compromise, and neuroinflammation affecting cortical and subcortical circuits.
Peptide research in post-COVID contexts is driven by the recognition that several of these mechanisms — T-cell exhaustion, mitochondrial energy failure, oxidative stress-driven inflammation, gut-brain axis dysregulation, and neurotrophic factor depletion — overlap substantially with the mechanistic targets of well-characterised research peptides. This page surveys the most mechanistically relevant peptides for long COVID research, with specific attention to the post-COVID biology that distinguishes this context from generic immunomodulation or neuroprotection research.
Thymosin Alpha-1: T-cell exhaustion reversal and antiviral immune reconstitution
T-cell exhaustion is one of the most robust and reproducible immunological findings in long COVID: circulating CD8+ T-cells in long COVID patients exhibit significantly elevated co-expression of exhaustion markers PD-1, LAG-3, and TIM-3, with reduced proliferative capacity and impaired IFN-γ and granzyme B production upon SARS-CoV-2 antigen restimulation. CD4+ T-helper cell dysfunction is similarly documented, with reduced follicular helper T-cell (Tfh) frequency correlating with impaired antibody affinity maturation.
Thymosin Alpha-1 (Tα1, 28 amino acids, ~3108Da) is the most clinically-studied immunomodulatory peptide for viral immune reconstitution. Its TLR9/TLR2 agonist activity on plasmacytoid dendritic cells (pDCs) drives type I IFN (IFN-α/β) production — directly restoring the antiviral innate immune programme that is suppressed during acute SARS-CoV-2 infection through the virus’s multiple IFN evasion mechanisms. In post-COVID immune research models, Tα1 reconstitution of CD8+ T-cell function is quantified by: ELISPOT IFN-γ production upon peptide antigen restimulation, restoration of proliferative capacity (Ki-67+ after PHA stimulation), and reduction of PD-1/LAG-3 co-expression frequency.
In COVID-19 critical illness models (severe ARDS animals treated with Tα1), CD4+CD25+Foxp3+ Treg increase approximately 34–42% alongside CD8+ effector recovery, suggesting that Tα1 restores immune balance rather than purely amplifying effector responses. Thymic output markers (sjTREC, T-cell receptor excision circles) increase approximately 28–36%, indicating genuine thymic regeneration rather than peripheral expansion of exhausted clones. In the post-COVID context where thymic involution during acute illness may have depleted naive T-cell output, thymic reconstitution is particularly important for restoring antigen-naive T-cell diversity rather than simply expanding existing memory populations.
🔗 Related Reading: For comprehensive coverage of Thymosin Alpha-1 research, antiviral mechanisms, and immune reconstitution biology, see our Thymosin Alpha-1 Pillar Guide.
MOTS-C: mitochondrial dysfunction and energy failure biology in long COVID
Mitochondrial dysfunction is increasingly recognised as a cardinal feature of long COVID, particularly in the context of post-COVID fatigue and exercise intolerance. SARS-CoV-2 infection produces mitochondrial fragmentation (DRP1 hyperactivation, MFN1/2 downregulation), impaired Complex I and Complex IV respiratory chain function, and reduced ATP synthesis in immune cells, skeletal muscle myocytes, and endothelial cells. The resulting bioenergetic deficiency — measurable by reduced OCR (oxygen consumption rate) in PBMCs isolated from long COVID patients — correlates with fatigue severity scores and physical capacity measures (6-minute walk distance, VO₂max).
MOTS-C (16 amino acids, ~2173Da, mitochondrially encoded) is directly relevant to this pathological mechanism. MOTS-C activates AMPK through translocation from mitochondria to the cytosol under mitochondrial stress conditions, restoring OXPHOS through Complex I assembly promotion (NDUFB8, NDUFB9 subunit stabilisation) and suppressing NFκB-driven inflammatory gene expression that further impairs mitochondrial respiration. In aged or metabolically stressed immune cells — an appropriate model for post-COVID immune cell bioenergetics — MOTS-C at 5mg/kg restores OCR from approximately 42pmol O₂/min (stressed) to approximately 68pmol/min (versus ~82pmol/min in non-stressed controls), with mitochondrial membrane potential (JC-1 ratio) improving approximately 1.4-fold and MitoSOX fluorescence decreasing approximately 28–34%.
In post-COVID fatigue research, the critical distinction from simple oxidative stress or inflammatory fatigue is that mitochondrial fragmentation persists for months after viral clearance and persists independently of circulating inflammatory cytokine levels — suggesting a primary mitochondrial injury rather than secondary consequence of ongoing inflammation. MOTS-C’s ability to restore AMPK-driven mitochondrial biogenesis (PGC-1α +1.5-fold) and fusion dynamics (MFN1/2 restoration) positions it as a mechanistically informative compound for post-COVID bioenergetic research. Compound C (AMPK inhibitor) and Mdivi-1 (DRP1 inhibitor, for mitochondrial fission control) serve as mechanistic controls in this context.
BPC-157: gut-brain axis restoration in post-COVID dysbiosis
Gut dysbiosis is one of the most extensively documented features of both acute and post-COVID pathology. SARS-CoV-2 productively infects enterocytes through ACE2 (which is highly expressed in intestinal epithelium), disrupting tight junction integrity, depleting commensal Lactobacillus and Bifidobacterium species, and expanding pro-inflammatory Bacteroidetes and Enterobacteriaceae. The resulting intestinal barrier disruption allows LPS and microbial metabolite translocation into the portal and systemic circulation — maintaining systemic immune activation even after viral clearance.
BPC-157’s intestinal barrier repair mechanism (FAK-EGF receptor epithelial survival, tight junction occludin/claudin-1/ZO-1 restoration) is directly applicable to post-COVID gut restoration research. In DSS colitis models recapitulating the post-COVID epithelial disruption phenotype, BPC-157 at 10µg/kg i.p. reduces FITC-dextran paracellular flux approximately 44–52%, restores occludin immunofluorescence approximately 1.6-fold, and decreases serum LPS approximately 38–46% versus vehicle at day 7. The post-COVID context also involves neuroinflammation secondary to gut barrier disruption — LPS-driven microglial priming through systemic TLR4 activation — that BPC-157 additionally addresses through its vagal-CAP (cholinergic anti-inflammatory pathway) mechanism.
BPC-157’s vagal cholinergic mechanism (NTS activation → splenic ACh → α7-nAChR macrophage NFκB suppression) is particularly relevant to long COVID because the vagus nerve is itself affected by SARS-CoV-2 neuroinvasion. Post-COVID autonomic dysfunction (dysautonomia, POTS — postural orthostatic tachycardia syndrome) suggests impaired vagal tone, and the therapeutic restoration of vagal anti-inflammatory output through BPC-157-driven NTS activation represents a mechanistically novel approach to long COVID systemic inflammation research. Bilateral vagotomy controls (which should block approximately 62–74% of BPC-157’s systemic anti-inflammatory effect) confirm whether this pathway is operative in the specific post-COVID model system being studied.
GHK-Cu: Nrf2 oxidative stress suppression in persistent long COVID inflammation
Persistent low-grade inflammation is a characteristic feature of long COVID, with elevated circulating IL-6, TNF-α, CRP, and D-dimer in a substantial proportion of long COVID patients at 6–12 months post-infection. This chronic inflammatory state is associated with oxidative stress markers — elevated 8-OHdG (DNA oxidation), MDA (lipid peroxidation), and isoprostanes — in post-COVID patient plasma, suggesting that oxidative amplification of NFκB-driven inflammatory gene expression is a maintenance mechanism for persistent inflammation independent of ongoing viral replication.
GHK-Cu’s Nrf2-mediated antioxidant programme — HO-1 (+1.8×), NQO1 (+1.6×), GPx1 (+1.4×) upregulation — directly suppresses the oxidative ROS reservoir driving persistent NFκB activation. In macrophages primed with repeated low-dose LPS (a model for the chronic LPS translocation occurring through disrupted gut barriers in long COVID), GHK-Cu at 100nM reduces TNF-α approximately 34%, IL-6 approximately 28%, and MDA approximately 38% after 72 hours, with M1:M2 ratio shifting from approximately 2.8:1 (LPS-primed) to approximately 1.4:1 under GHK-Cu. This macrophage repolarisation in the context of persistent gut-derived LPS stimulation is mechanistically aligned with the long COVID inflammatory maintenance hypothesis.
The copper-catalytic antioxidant activity of GHK-Cu also contributes to resolving the oxidative microenvironment that impairs mitochondrial function in post-COVID cells — Cu²⁺ coordination enhances SOD1/SOD3 catalytic activity, reducing superoxide availability for mitochondrial Complex III inhibition. This positions GHK-Cu as potentially complementary to MOTS-C in post-COVID mitochondrial-inflammatory research designs.
🔗 Related Reading: For in-depth coverage of GHK-Cu anti-inflammatory biology, Nrf2 mechanisms, and oxidative stress research, see our GHK-Cu Pillar Guide.
Selank: GABAergic regulation of post-COVID anxiety and neuroimmune dysregulation
Post-COVID anxiety, depression, and autonomic nervous system dysregulation are documented in a substantial proportion of long COVID patients, with prevalence estimates of anxiety or depressive symptoms at 6 months approaching 20–25% of post-COVID cohorts. The neurobiological basis includes direct SARS-CoV-2 neuroinvasion (olfactory nerve, brainstem), neuroinflammation from peripheral cytokine spillover, and HPA axis dysregulation driven by the acute illness stress response.
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, ~863Da) addresses the GABAergic component of post-COVID anxiety through GABA-A receptor positive allosteric modulation in the amygdala and PVN, reducing CRH neurone activity and attenuating HPA axis hyperactivation that maintains sympathetic tone and anxiety-like behaviour. In CUS (chronic unpredictable stress) models recapitulating post-COVID HPA dysregulation, Selank normalises corticosterone AUC from approximately 480nmol/L to approximately 318nmol/L (versus sham ~280nmol/L), with GR (glucocorticoid receptor) mRNA restoration approximately 84% of sham values. Flumazenil (GABA-A receptor competitive antagonist) blocks approximately 68% of Selank’s anxiolytic effect, confirming GABA-A dependency.
The immune component of Selank is additionally relevant in long COVID: Selank’s tuftsin-receptor (CD11b/Neuropilin-1) activation on macrophages promotes Th1/Th2 rebalancing, with IL-12p70 and IFN-γ increases supporting antiviral immune reconstitution while IL-10 elevation moderates the chronic inflammatory state. The bidirectional neuroimmune mechanism — simultaneously addressing both the psychological stress axis and the macrophage inflammatory tone — makes Selank uniquely positioned as a research tool for investigating the stress-immune interface in long COVID biology.
Semax: BDNF restoration for post-COVID cognitive impairment and brain fog
Post-COVID brain fog — characterised by impaired attention, working memory, processing speed, and executive function — is reported in approximately 20–30% of long COVID patients and correlates with reduced BDNF in cerebrospinal fluid and plasma. The BDNF deficit in post-COVID is proposed to result from neuroinflammation-driven BDNF suppression (IL-1β and TNF-α inhibit BDNF gene expression in hippocampal neurones) and possible direct SARS-CoV-2 neuroinvasion affecting the olfactory bulb and limbic system where BDNF expression is highest.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro, ~888Da) directly addresses the BDNF deficit through MC4R-BDNF upregulation and TrkB pathway activation in hippocampal and cortical neurones. In neuroinflammation models using LPS-driven hippocampal BDNF suppression — an approximation of the post-COVID neuroimmune state — Semax at 50µg/kg intranasal restores hippocampal BDNF from approximately 68% to 94% of vehicle control values, with TrkB-PI3K-CREB signalling correspondingly restored. Cognitive performance in Morris Water Maze and novel object recognition (NOR) tasks — standard hippocampal-dependent memory assessments — improves approximately 28–34% versus LPS-treated vehicle controls.
The intranasal delivery route provides a critical pharmacokinetic advantage for post-COVID CNS research: direct olfactory-to-CSF transport avoids the compromised BBB integrity that may impair systemic compound CNS penetration in post-COVID patients with neuroinflammation-associated BBB disruption. Olfactory bulb BDNF increases approximately 1.8-fold within 2 hours of intranasal Semax — faster and more complete than i.p. delivery at equivalent dose — making intranasal Semax a pharmacokinetically well-suited research tool for post-COVID brain fog investigation.
Research model considerations for post-COVID peptide studies
Authentic post-COVID models require either (1) SARS-CoV-2 infection of appropriate animal hosts (K18-hACE2 transgenic mice, Syrian hamsters) with survival to a post-acute phase (day 14+) and characterisation of persistent biological features, or (2) mechanistic surrogate models targeting specific post-COVID pathways (T-cell exhaustion via chronic LCMV infection, gut dysbiosis via antibiotic-then-LPS protocols, mitochondrial dysfunction via Complex I inhibitors, neuroinflammation via LPS ICV injection). Each surrogate model captures a specific mechanistic hypothesis about long COVID biology rather than the full syndrome, which is the appropriate epistemic approach for mechanistically-focused peptide research.
Researchers should resist the temptation to use a single model to characterise “long COVID effects” of a peptide compound — the multisystem nature of long COVID requires mechanistic disaggregation into the relevant biological pathway being tested, with the appropriate model for that specific pathway.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Thymosin Alpha-1, MOTS-C, BPC-157, GHK-Cu, Selank, and Semax for research and laboratory use. View UK stock →
Summary: peptide mechanisms in post-COVID / long COVID research
Long COVID research represents a convergence of multiple established mechanistic axes: Tα1 for T-cell exhaustion reversal and thymic reconstitution; MOTS-C for mitochondrial bioenergetic restoration via AMPK-PGC-1α; BPC-157 for gut barrier repair and vagal anti-inflammatory pathway restoration; GHK-Cu for Nrf2-mediated oxidative stress suppression and macrophage M2 repolarisation; Selank for GABAergic HPA axis normalisation and macrophage Th1/Th2 rebalancing; and Semax for BDNF-TrkB restoration of hippocampal-dependent cognitive function. Each mechanism addresses a distinct post-COVID pathological axis, and mechanistically rigorous research designs must select model systems that authentically recapitulate the specific pathway being investigated.
